Welcome to our dedicated page for Pulmonx SEC filings (Ticker: LUNG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pulmonx Corporation SEC filings document the company’s medical technology business, Nasdaq-listed common stock and formal disclosures around operating results, governance, compensation and capital structure. Recent 8-K filings furnish quarterly and annual financial results for the Zephyr Valve-focused lung disease treatment business, including revenue by geography, gross margin, restructuring activity and related management commentary.
The filing record also includes material agreement disclosures for a senior secured term loan facility, proxy materials covering annual meeting proposals, director elections, auditor ratification and executive compensation votes, and 8-K disclosures tied to leadership transitions, separation arrangements and inducement equity awards.